TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Earnings Flash·November 12, 2026

Twist Bioscience Corporation (TWST) falls on earnings beats

Twist Bioscience Corporation (TWST) falls after earnings beats, with shares down 12.0% as investors react to the latest quarterly results and outlook.

Earnings FlashTWSTHealthcareBiotechnology
By TickerSpark·November 12, 2026·2 min read
Twist Bioscience Corporation (TWST) falls on earnings beats
▌Key Takeaway
Twist Bioscience Corporation (NASDAQ: TWST) beat Wall Street estimates on both earnings and revenue, but the stock still fell 12.03% in regular-session trading. The quarter showed improvement, with the loss narrowing to -$0.32 per share from -$0.56 in August, yet investors appear unconvinced that the better results are enough to justify a higher valuation.

Twist Bioscience Corporation (TWST) Earnings Beat, Stock Falls

Twist Bioscience Corporation (TWST) beat estimates with EPS of -$0.32 and revenue of $0.13B, yet the stock fell 12.03% to $107.84 in regular-session trading.

Key Numbers

  • EPS: -$0.32 actual versus -$0.38707 estimated, a beat.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Revenue: $0.13B actual versus $0.12B estimated, a beat.
  • Price reaction: $107.84 regular-session close, down 12.03% from $122.59.
  • Trading range and volume: $93.67 to $108.00, with 1,634,358 shares traded versus a 2,367,237 average.
  • Trend: The EPS loss narrowed from -$0.56 in August 2026 to -$0.32 now, following three straight quarterly misses.

    • A Stronger Quarter Meets a Skeptical Market

    The central signal in these TWST earnings is a split verdict. The company beat on EPS and revenue, yet the stock fell 12.03% in regular-session trading. The operating result was positive against estimates, but it did not translate into price support.

    For a $7.1B biotech, that gap makes the earnings call important. Management's explanation of the 12.03% decline deserves attention, along with any detail tying the $0.13B revenue result to demand that can continue. Those points would help investors judge whether the quarter marks progress or a one-quarter improvement.

    Recent history gives the beat some weight. TWST had three straight EPS misses in February, May, and August 2026. The loss then narrowed from -$0.56 in August to -$0.32 now. The current result is also the narrowest loss in the five-quarter record listed, but the 12.03% drop shows the smaller loss was insufficient to support the stock on the day.

    Get AI research on any stock

    Instant reports, daily intelligence, and an AI analyst in your pocket.

    Get Started →

    Bottom Line

    TWST delivered a genuine EPS and revenue beat, but the 12.03% regular-session selloff keeps the focus on whether narrower losses can become a durable trend.

    Read the full TWST research report
    ▌Common Questions

    Frequently asked questions

    +Why did Twist Bioscience stock fall even though TWST beat earnings estimates?
    Twist Bioscience beat EPS and revenue estimates, but the market still sold the stock off 12.03% to $107.84. The reaction suggests investors were more focused on the quality and durability of the improvement than the headline beat.
    +What were Twist Bioscience's latest earnings and revenue results?
    Twist Bioscience reported EPS of -$0.32 versus an estimated -$0.38707, and revenue of $0.13 billion versus an estimated $0.12 billion. Both results came in ahead of expectations.
    +How much did TWST stock move after earnings?
    TWST fell 12.03% in regular-session trading and closed at $107.84, down from $122.59. The stock traded between $93.67 and $108.00 on volume of 1,634,358 shares.
    +Is Twist Bioscience improving compared with prior quarters?
    Yes, the loss narrowed from -$0.56 in August 2026 to -$0.32 in the latest quarter. The company also broke a streak of three straight quarterly EPS misses, making this its strongest recent earnings result on the record provided.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on TWST?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the TWST report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full TWST research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the TWST report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on TWST

    More to read

    All articles
    Twist Bioscience Corporation (TWST) drops on deep earnings beat
    TWST

    Twist Bioscience Corporation (TWST) drops on deep earnings beat

    Twist Bioscience Corporation (TWST) beat earnings and revenue estimates, yet the stock drops as investors weigh valuation, margin progress and growth expectations. This deep-dive examines the company’s 15th straight quarter of sequential revenue growth, AI drug discovery momentum, NGS expansion and the path toward sustained profitability.

    Nov 12·6 min
    Twist Bioscience (TWST): AI Discovery and Margin Leverage
    TWST

    Twist Bioscience (TWST): AI Discovery and Margin Leverage

    Twist Bioscience is posting strong revenue growth and improving margins, but valuation remains demanding. The stock earns a Hold as the company works toward adjusted EBITDA breakeven in fiscal Q4 2026.

    Nov 2·18 min
    Twist Bioscience Corporation (TWST) rises on deep earnings analysis
    TWST

    Twist Bioscience Corporation (TWST) rises on deep earnings analysis

    Twist Bioscience Corporation (TWST) rose after a mixed quarter that featured an EPS miss but a revenue beat, continued sequential growth, and improving segment momentum. This deep dive examines the margin expansion, adjusted EBITDA breakeven path, and why investors focused on the bigger operating picture.

    Aug 3·7 min